Experience of use of everolimus and long-acting somatostatin analogues combination in highly differentiated (G1-G2) neuroendocrine tumors
- 作者: Markovich A1, Kuzminov A1, Orel N1, Odintsova A1, Emelyanova G2, Gorbunova V1
-
隶属关系:
- N.N.Blokhin Russian Cancer Research Center of the Ministry of Health of the Russian Federation
- A.I.Evdokimov Moscow State Medical and Dental University of the Ministry of Health of the Russian Federation
- 期: 卷 17, 编号 3 (2015)
- 页面: 92-95
- 栏目: Articles
- URL: https://journals.rcsi.science/1815-1434/article/view/27038
- ID: 27038
如何引用文章
全文:
详细
作者简介
A Markovich
N.N.Blokhin Russian Cancer Research Center of the Ministry of Health of the Russian Federation
Email: a-markovich@yandex.ru
канд. мед. наук, ст. науч. сотр. научно-консультативного отд-ния ФГБУ РОНЦ им. Н.Н.Блохина 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23
A Kuzminov
N.N.Blokhin Russian Cancer Research Center of the Ministry of Health of the Russian Federationканд. мед. наук, науч. сотр. отд-ния химиотерапии ФГБУ РОНЦ им. Н.Н.Блохина 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23
N Orel
N.N.Blokhin Russian Cancer Research Center of the Ministry of Health of the Russian Federationд-р мед. наук, вед. науч. сотр. отд-ния химиотерапии ФГБУ РОНЦ им. Н.Н.Блохина 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23
A Odintsova
N.N.Blokhin Russian Cancer Research Center of the Ministry of Health of the Russian Federationканд. мед. наук, врач-онколог отд-ния химиотерапии ФГБУ РОНЦ им. Н.Н.Блохина 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23
G Emelyanova
A.I.Evdokimov Moscow State Medical and Dental University of the Ministry of Health of the Russian Federationканд. мед. наук, сотр. каф. онкологии фак-та дополнительного проф. образования ГБОУ ВПО МГМСУ им. А.И.Евдокимова 127473, Russian Federation, Moscow, ul. Delegatskaia, d. 20, str. 1
V Gorbunova
N.N.Blokhin Russian Cancer Research Center of the Ministry of Health of the Russian Federationд-р мед. наук, проф., зав. отд-нием химиотерапии ФГБУ РОНЦ им. Н.Н.Блохина 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23
参考
- Yao J.C, Phan A.T, Chang D.Z et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low - to intermediate - grade neuroendocrine tumors: results of a phase II study. J Clin Oncol 2008; 26 (26): 4311-8.
- Yao J.C, Lombard-Bohas C, Baudin E et al. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumours after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol 2010; 28: 69-76.
- Duran I, Kortmansky J, Singh D et al. A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Brit J Cancer 2006; 95: 1148-54.
- Susini C, Buscail L. Rationale for the use of somatostatin analogs as antitumor agents. Ann Oncol 2006; 17: 1733-42.
- Pavel M, Hainsworth J.D, Baudin E et al. A randomized, double - blind, placebo - controlled, multicenter phase III trial of everolimus + octreotide LAR vs. placebo + octreotide lar in patients with advanced neuroendocrine tumors - NET (RADIANT-2). Abstr. LBA8. 35th ESMO Congress. Milan, 8-12 Oct 2010.
- Yao J.C, Shah M.H, Ito T et al. A randomized, double - blind, placebo - controlled, multicenter phase III trial of everolimus in patients with advanced pancreatic neuroendocrine tumors - PNET (RADIANT-3). Abstr. LBA9 35th ESMO Congress. Milan, 8-12 Oct 2010.